Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PRESS RELEASE : Gerresheimer AG: Gerresheimer with positive start to the financial year 2021

04/08/2021 | 01:08am EDT
DGAP-News: Gerresheimer AG / Key word(s): Quarterly / Interim Statement 
Gerresheimer AG: Gerresheimer with positive start to the financial year 2021 
2021-04-08 / 07:06 
The issuer is solely responsible for the content of this announcement. 
Gerresheimer with positive start to the financial year 2021 
- Organic revenue growth of 3.1 % in core business 
- Strong development in High Value Solutions: Focus on Biological Solutions pays off 
- Adjusted EBITDA increases organically by 7.0 % in core business 
- Adjusted earnings per share rise organically by 29.3 % to EUR 0.57 
- Guidance confirmed for the financial year 2021 
Duesseldorf, April 8, 2021 - "We got off to a good start in the financial year," said Dietmar Siemssen, CEO of 
Gerresheimer AG. "Our high value products and solutions for biotech and pharma companies saw significant growth in the 
first quarter. The order books are full. We are well on our way to achieving our targets for 2021. The achievements 
which are now becoming visible, confirm the effectiveness of our growth strategy, which will continue to roll out 
In the first quarter of 2021, Gerresheimer Group generated revenues of EUR 303m. Revenues in core business increased 
organically by 3.1% year on year. The Plastics & Devices Division grew organically by 3.0% in the first quarter of 
2021, thanks in particular to the syringes business and the demand for pharmaceutical plastic packaging. 
Currency-adjusted sales were up 3.2% year on year in the Primary Packaging Glass Division, even though the cosmetics 
business in the Moulded Glass Business Unit continued to feel the negative effects of the Covid-19 pandemic. The pharma 
business benefited in the first quarter from growing demand for high value solutions and products such as Gx RTF 
syringe systems, Gx Elite Glass and Gx RTF Vials, particularly for biopharmaceuticals. 
The Company continued to expand its production capacities for manufacturing injection vials for Covid-19 vaccines in 
the first quarter of 2021. By doing so, the Company is reaffirming its responsibility and making an important 
contribution to combating the pandemic by supplying glass vials to be filled with vaccines. 
Adjusted EBITDA stood at EUR 54m in the first quarter of 2021. In the core business, adjusted EBITDA rose organically 
by 7.0% year on year to EUR 57m. The adjusted EBITDA margin in the core business amounted to 19.0%. The adjusted net 
income was EUR 18m, resulting in adjusted earnings per share of EUR 0.57 with an increase of organically 29.3% (32.6 % 
as reported) compared to the same quarter in the prior year. 
Outlook for the financial year 2021 (core business, currency-adjusted): 
- Revenues growth in the mid single-digit percentage range 
- Adjusted EBITDA margin between 22% and 23% 
- Adjusted earnings per share in euros to increase by at least 10% 
Medium term (core business, net of currency effects): 
- Revenues growth in the high single-digit percentage range 
- Adjusted EBITDA margin of around 23% 
- Adjusted earnings per share in euros to increase by at least 10% per year 
The Quarterly Statement for the first quarter of 2021 is available here: 
Press contact 
Jens Kürten 
Group Senior Director Communication & Marketing 
T +49 211 6181-250 
Investor Relations contact 
Carolin Nadilo 
Corporate Director Investor Relations 
T +49 211 6181-220 
About Gerresheimer 
Gerresheimer is the global partner for pharma, biotech, healthcare and cosmetics with a very broad product range for 
pharmaceutical and cosmetic packaging and drug delivery devices. The company is an innovative solution provider from 
concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative 
strength, industrial competence, focus on quality and customers. In developing innovative and sustainable solutions, 
Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, 
America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generates 
annual sales of more than EUR1.4 billion. With its products and solutions, Gerresheimer plays an essential role in 
people's health and well-being. 
2021-04-08 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:     English 
Company:      Gerresheimer AG 
              Klaus-Bungert-Str. 4 
              40468 Düsseldorf 
Phone:        +49-(0)211/61 81-314 
Fax:          +49-(0)211/61 81-121 
E-mail:       carolin.nadilo@gerresheimer.com 
Internet:     http://www.gerresheimer.com 
ISIN:         DE000A0LD6E6 
WKN:          A0LD6E 
Indices:      MDAX (Aktie) 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1182130 
End of News   DGAP News Service 

1182130 2021-04-08

(END) Dow Jones Newswires

April 08, 2021 01:07 ET (05:07 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
GERRESHEIMER AG 0.74% 89.05 Delayed Quote.1.48%
MDAX 0.78% 33263.21 Delayed Quote.8.01%
All news about GERRESHEIMER AG
04/13GERRESHEIMER  : participates in the European joint project Furnace for the Futur..
04/09GERRESHEIMER AG  : Gets a Sell rating from Independant Research
04/08GERRESHEIMER AG  : JP Morgan remains Neutral
04/08Global markets live: CVC, Twitter, Hitachi...
04/08GERRESHEIMER  : Presentation 1st Quarter 2021
04/08GERRESHEIMER AG  : JP Morgan sticks Neutral
04/08GERRESHEIMER AG  : Gets a Buy rating from Goldman Sachs
04/08GERRESHEIMER AG  : Berenberg reiterates its Buy rating
04/08GERRESHEIMER  : Fiscal Q1 Profit More Than Doubles on Operating Income Growth
04/08PRESS RELEASE  : Gerresheimer AG: Gerresheimer with positive start to the financ..
More news
Sales 2021 1 481 M 1 774 M 1 774 M
Net income 2021 112 M 135 M 135 M
Net Debt 2021 935 M 1 120 M 1 120 M
P/E ratio 2021 24,8x
Yield 2021 1,55%
Capitalization 2 796 M 3 350 M 3 350 M
EV / Sales 2021 2,52x
EV / Sales 2022 2,35x
Nbr of Employees 9 904
Free-Float 100%
Duration : Period :
Gerresheimer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GERRESHEIMER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 102,14 €
Last Close Price 89,05 €
Spread / Highest target 29,1%
Spread / Average Target 14,7%
Spread / Lowest Target -15,8%
EPS Revisions
Managers and Directors
Dietmar Siemssen Chief Executive Officer
Bernd Metzner Chief Financial Officer
Axel Herberg Chairman-Supervisory Board
Theodor Stuth Member-Supervisory Board
Udo Johannes Vetter Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC7.44%169 655